ANIPANIPHealthcare · Drug Manufacturers - Specialty & Generic

ANIP Stock Forecast: ANI Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$72
+2.19% on the day

The 8 Wall Street analysts covering ANI Pharmaceuticals, Inc. hold a median 12-month price target of $102 — +42.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 17 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.6B
Ticker Nerd rank
98/ 100
Median analyst target
$102
Analysts covering
8
Revenue$266.0M+25.9% y/y
Operating income$39.8M
Net income$24.7M
Free cash flow$53.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.6%
1M
−1.1%
YTD
−9.4%
1Y
−11.8%
From 52W high
−16.9%
From 52W low
+6.1%
$67
$86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANIP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ANI Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
98/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Volatility
98
Quality
94
Growth
90
Accruals
80
Issuance
70
Revisions
65
Momentum
54
Size
37

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (54): The shares have been drifting down relative to others.

Size (37): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ANIP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANIP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$70$80$90$100$110$120Jan 26Apr 26Jul 26Oct 26ANIPHigh $121Median $102Low $85

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
6 Buy2 Hold0 Sell
Low $85Median $102High $121

The green dot is the last close — the median target sits +42.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Nov 2026GuggenheimMaintainsBuy$119 → $121
23 Sept 2026OppenheimerInitiatesPerform—
23 Sept 2026OppenheimerInitiatesPerform$85
10 Aug 2026Canaccord GenuityMaintainsHold$91 → $90
10 Aug 2026Canaccord GenuityMaintainsHold—
10 Aug 2026GuggenheimMaintainsBuy—
10 Aug 2026GuggenheimMaintainsBuy$124 → $119
17 July 2026Canaccord GenuityInitiatesHold—
17 July 2026Canaccord GenuityInitiatesHold$91
10 July 2026GuggenheimReiteratesBuy—
10 July 2026GuggenheimReiteratesBuy$124
16 Jan 2026GuggenheimMaintainsBuy—
9 Dec 2025BarclaysInitiatesOverweight—
10 Nov 2025GuggenheimMaintainsBuy—
9 Oct 2025Truist SecuritiesMaintainsHold—
24 Sept 2025JP MorganMaintainsOverweight—
17 Sept 2025HC Wainwright & Co.MaintainsBuy—
8 Sept 2025GuggenheimMaintainsBuy—
11 Aug 2025Truist SecuritiesMaintainsHold—
8 Aug 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ANIP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ANIP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, ANI Pharmaceuticals, Inc. returned −11.8% against +12.2% for the S&P 500, dividends included.

ANIP vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26ANIPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANIP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+2.3%
Analysts raising
5
Analysts cutting
0
Fundamentals

ANI Pharmaceuticals, Inc. (ANIP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.9×

Cheaper than 46% of US stocks

Price / sales
1.5×

Cheaper than 56% of US stocks

Price / book
2.3×

Cheaper than 36% of US stocks

EV / EBITDA
7.1×

Cheaper than 47% of US stocks

Growth & margins
Revenue growth (YoY)
27.6%

Higher than 76% of US stocks

Earnings growth (YoY)
32.1%

Higher than 67% of US stocks

Gross margin
62.4%

Higher than 75% of US stocks

Operating margin
14.7%

Higher than 73% of US stocks

Net margin
11.2%

Higher than 71% of US stocks

Returns & dividend
Return on equity
20.4%

Higher than 81% of US stocks

Return on assets
6.4%

Higher than 82% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ANI Pharmaceuticals, Inc. (ANIP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ANI Pharmaceuticals, Inc. has a market value of $1.6B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $978.4M. The latest quarter grew 27.6% year on year.

  • Net income over the same four quarters: $108.3M, a 11.1% net margin.

  • Diluted earnings per share, trailing twelve months: $4.64.

  • Free cash flow in the twelve months to 30 June 2026: $167.5M.

  • ANI Pharmaceuticals, Inc. spent $344K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 23.0M.

  • Trailing P/E: 13.9×; forward P/E: 6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ANI Pharmaceuticals, Inc. employs 970 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

ANIP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ANIPANI Pharmaceuticals, Inc.$1.6B98
ALVOAlvotech$1.6B32
PCRXPacira Biosciences, Inc.$1.5B100
PAHCPhibro Animal Health Corp.$1.4B92
ETONEton Pharmaceuticals, Inc.$1.8B99
BCRXBioCryst Pharmaceuticals, Inc.$1.9B82
AMPHAmphastar Pharmaceuticals, Inc.$1.3B94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ANI Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANIP news & analysis

Here's Why ANI Pharmaceuticals (ANIP) is a Strong Value Stock

Zacks Investment Research · 17 Nov 2026positive

Zacks Investment Research says its Style Scores help investors identify stocks rated highly for a particular investing style, and presents ANI Pharmaceuticals as a strong value stock.

Why it matters — The item frames ANIP through Zacks’ value-investing style assessment, which may interest investors tracking how the stock is categorized.

ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript

Seeking Alpha · 7 Nov 2026neutral

ANI Pharmaceuticals held its third-quarter 2026 earnings call on November 5, 2026. The excerpt lists company executives and participating analysts but does not include discussion of results or business updates.

Why it matters — The transcript identifies the call and its participants, but the excerpt provides no details about quarterly performance for ANIP watchers to assess.

ANI Pharmaceuticals Q3 Earnings Call Highlights

MarketBeat · 5 Nov 2026neutral

ANI Pharmaceuticals reported 28% revenue growth in the third quarter of 2026 and announced an offer to acquire Egetis Therapeutics for $560 million in equity value. It also lowered its full-year Cortrophin Gel sales outlook, citing pharmacy bottlenecks that slowed the conversion of new patient cases into treatment.

Why it matters — The update combines strong quarterly revenue growth and a proposed acquisition with a reduced Cortrophin Gel sales outlook.

ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 5 Nov 2026neutral

Zacks says ANI Pharmaceuticals’ headline earnings numbers for the quarter ended September 2026 offer insight into its performance. The excerpt suggests comparing key metrics with Wall Street estimates and year-ago actuals but provides no specific figures or results.

Why it matters — ANIP watchers may use comparisons with analyst estimates and the year-ago quarter to assess the company’s reported performance.

ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

Zacks Investment Research · 5 Nov 2026positive

ANI Pharmaceuticals reported quarterly earnings of $2.70 per share, above the Zacks Consensus Estimate of $2.17. Earnings were $2.04 per share in the year-ago quarter.

Why it matters — The earnings beat and year-over-year comparison are relevant to investors following ANIP’s quarterly results.

FAQ

Frequently asked questions about ANIP stock

What is the ANIP stock price forecast for 2026-2027?

The 8 Wall Street analysts covering ANI Pharmaceuticals, Inc. have a median 12-month price target of $102, with estimates ranging from $85 to $121. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANIP stock a buy right now?

Of the 8 analysts covering ANI Pharmaceuticals, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ANI Pharmaceuticals, Inc. 98 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANIP?

As at 17 Nov 2026, ANI Pharmaceuticals, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will ANIP stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +42.6% from the last close, and Ticker Nerd's factor model ranks ANI Pharmaceuticals, Inc. 98 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANIP stock forecast for 2030?

No analyst covering ANI Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $121 over the next 12 months.

How has ANIP stock performed over the past year?

ANI Pharmaceuticals, Inc. returned -11.8% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ANI Pharmaceuticals, Inc. do?

ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes branded, generic, and specialty prescription medicines.

What is the latest news on ANIP?

The most recent item we track (Zacks Investment Research, 17 Nov 2026): "Here's Why ANI Pharmaceuticals (ANIP) is a Strong Value Stock". Zacks Investment Research says its Style Scores help investors identify stocks rated highly for a particular investing style, and presents ANI Pharmaceuticals as a strong value stock.

Company

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes branded, generic, and specialty prescription medicines. ANI Pharmaceuticals focuses on three main areas: Rare Disease, Generics, and Established Brands. Its portfolio includes therapies for ophthalmology, rheumatology, nephrology, neurology, and pulmonology, alongside a broad range of generic products and established branded medicines. The company also supports contract manufacturing and pharmaceutical development services, leveraging U.S.-based manufacturing capabilities and expertise in complex formulations such as injectables, softgels, oral solids, liquids, and topical products. ANI Pharmaceuticals serves patients, pharmacies, wholesalers, specialty channels, and other healthcare customers through a diversified commercial model built around prescription pharmaceuticals and niche therapeutic markets.

CEO Mr. Nikhil Lalwani · 970 employees · United States · https://www.anipharmaceuticals.com